BACKGROUND: The frequency and severity of invasive fungal infections in immunocompromised patients has increased steadily over the last 2 decades. In response to the increased incidence and high mortality rates, novel antifungal agents have been developed to expand the breadth and effectiveness of treatment options available to clinicians. Despite these therapeutic advances, the impact of the availability of new antifungal agents on pediatric practice is unknown. METHODS: A retrospective cohort study was conducted using the Pediatric Health Information System database to describe the changes in pediatric antifungal therapy at 25 freestanding United States children's hospitals from 2000 to 2006. All pediatric inpatients who received a charge for one or more of the following agents were included in the analysis: conventional amphotericin B (AMB), lipid amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine, caspofungin, and micafungin. Underlying conditions and fungal infection status were ascertained. RESULTS: A total of 62,842 patients received antifungal therapy, with prescriptions significantly increasing during the 7-year study period (P = 0.03). The most commonly prescribed antifungal agent was fluconazole (76%), followed by amphotericin preparations (26%). Prescription of AMB steadily decreased from 2000 to 2006 (P = 0.02). Prescription of voriconazole steadily increased during the study period and replaced AMB for the treatment of aspergillosis. The echinocandins steadily increased in prescription for treatment of fungal infections, particularly in disseminated/systemic candidiasis. CONCLUSIONS: We found that the number of pediatric inpatients requiring antifungal therapy has increased significantly and the choice of treatment has changed dramatically with the introduction of newer antifungal agents.
BACKGROUND: The frequency and severity of invasive fungal infections in immunocompromised patients has increased steadily over the last 2 decades. In response to the increased incidence and high mortality rates, novel antifungal agents have been developed to expand the breadth and effectiveness of treatment options available to clinicians. Despite these therapeutic advances, the impact of the availability of new antifungal agents on pediatric practice is unknown. METHODS: A retrospective cohort study was conducted using the Pediatric Health Information System database to describe the changes in pediatric antifungal therapy at 25 freestanding United States children's hospitals from 2000 to 2006. All pediatric inpatients who received a charge for one or more of the following agents were included in the analysis: conventional amphotericin B (AMB), lipidamphotericin B, fluconazole, itraconazole, voriconazole, flucytosine, caspofungin, and micafungin. Underlying conditions and fungal infection status were ascertained. RESULTS: A total of 62,842 patients received antifungal therapy, with prescriptions significantly increasing during the 7-year study period (P = 0.03). The most commonly prescribed antifungal agent was fluconazole (76%), followed by amphotericin preparations (26%). Prescription of AMB steadily decreased from 2000 to 2006 (P = 0.02). Prescription of voriconazole steadily increased during the study period and replaced AMB for the treatment of aspergillosis. The echinocandins steadily increased in prescription for treatment of fungal infections, particularly in disseminated/systemic candidiasis. CONCLUSIONS: We found that the number of pediatric inpatients requiring antifungal therapy has increased significantly and the choice of treatment has changed dramatically with the introduction of newer antifungal agents.
Authors: Daniel K Benjamin; Barbara J Stoll; Avory A Fanaroff; Scott A McDonald; William Oh; Rosemary D Higgins; Shahnaz Duara; Kenneth Poole; Abbot Laptook; Ronald Goldberg Journal: Pediatrics Date: 2006-01 Impact factor: 7.124
Authors: Theoklis E Zaoutis; Kateri Heydon; Russell Localio; Thomas J Walsh; Chris Feudtner Journal: Clin Infect Dis Date: 2007-03-19 Impact factor: 9.079
Authors: L Saiman; E Ludington; M Pfaller; S Rangel-Frausto; R T Wiblin; J Dawson; H M Blumberg; J E Patterson; M Rinaldi; J E Edwards; R P Wenzel; W Jarvis Journal: Pediatr Infect Dis J Date: 2000-04 Impact factor: 2.129
Authors: Theoklis E Zaoutis; Kateri Heydon; Jaclyn H Chu; Thomas J Walsh; William J Steinbach Journal: Pediatrics Date: 2006-03-13 Impact factor: 7.124
Authors: P Brian Smith; Juliette Morgan; J Daniel K Benjamin; Scott K Fridkin; Laurie Thomson Sanza; Lee H Harrison; Andre N Sofair; Sharon Huie-White; Daniel K Benjamin Journal: Pediatr Infect Dis J Date: 2007-03 Impact factor: 2.129
Authors: Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect Journal: N Engl J Med Date: 2002-12-19 Impact factor: 91.245
Authors: Simon B Ascher; P Brian Smith; Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez; Reese H Clark; Daniel K Benjamin; Cassandra Moran Journal: Pediatr Infect Dis J Date: 2012-05 Impact factor: 2.129
Authors: Jennifer L Goldman; Rachael K Ross; Brian R Lee; Jason G Newland; Adam L Hersh; Matthew P Kronman; Jeffrey S Gerber Journal: Infect Control Hosp Epidemiol Date: 2017-03-15 Impact factor: 3.254
Authors: J Kevin Hicks; Kristine R Crews; Patricia Flynn; Cyrine E Haidar; Calvin C Daniels; Wenjian Yang; John C Panetta; Deqing Pei; Jeffrey R Scott; Alejandro R Molinelli; Ulrich Broeckel; Deepa Bhojwani; William E Evans; Mary V Relling Journal: Pharmacogenomics Date: 2014-06 Impact factor: 2.533
Authors: Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin Journal: Clin Pharmacokinet Date: 2014-07 Impact factor: 6.447
Authors: Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin Journal: Clin Pharmacokinet Date: 2014-05 Impact factor: 6.447